Source: Eur Respir J 2009; 34: 7-9
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Provencher S. , Sitbon O.. Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence. Eur Respir J 2009; 34: 7-9

Member's Comments

No comment yet.

Related content which might interest you: Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 339-343 Year: 2002 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Experience with inhaled iloprost in paediatric pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution Source: Eur Respir J, 55 (6) 1902418; 10.1183/13993003.02418-2019 Year: 2020 Inhaled iloprost in HIV-related pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Inhaled iloprost for patients with pulmonary arterial hypertension and right heart failure Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management Year: 2017 Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005